DMRA
Price
$28.10
Change
+$1.26 (+4.69%)
Updated
Sep 11 closing price
Capitalization
1.74B
48 days until earnings call
Intraday BUY SELL Signals
VIVS
Price
$0.28
Change
-$0.02 (-6.67%)
Updated
Sep 11 closing price
Capitalization
3.76M
Intraday BUY SELL Signals
Interact to see
Advertisement

DMRA vs VIVS

DMRA vs VIVS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DMRA vs. VIVS commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMRA is a StrongBuy and VIVS is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DMRA($1.74B) has a higher market cap than VIVS($3.76M). DMRA YTD gains are higher at: 22.121 vs. VIVS (-84.359). VIVS has higher annual earnings (EBITDA): -12.13M vs. DMRA (-270.56M). DMRA has more cash in the bank: 541M vs. VIVS (1.67M). VIVS has higher revenues than DMRA: VIVS (112K) vs DMRA (0).
DMRAVIVSDMRA / VIVS
Capitalization1.74B3.76M46,207%
EBITDA-270.56M-12.13M2,231%
Gain YTD22.121-84.359-26%
P/E RatioN/A0.47-
Revenue0112K-
Total Cash541M1.67M32,395%
Total DebtN/A316K-
FUNDAMENTALS RATINGS
DMRA vs VIVS: Fundamental Ratings
DMRA
VIVS
OUTLOOK RATING
1..100
814
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
17
Undervalued
PROFIT vs RISK RATING
1..100
32100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3494
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
27n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VIVS's Valuation (17) in the Biotechnology industry is in the same range as DMRA (35) in the null industry. This means that VIVS’s stock grew similarly to DMRA’s over the last 12 months.

DMRA's Profit vs Risk Rating (32) in the null industry is significantly better than the same rating for VIVS (100) in the Biotechnology industry. This means that DMRA’s stock grew significantly faster than VIVS’s over the last 12 months.

DMRA's SMR Rating (99) in the null industry is in the same range as VIVS (100) in the Biotechnology industry. This means that DMRA’s stock grew similarly to VIVS’s over the last 12 months.

DMRA's Price Growth Rating (34) in the null industry is somewhat better than the same rating for VIVS (94) in the Biotechnology industry. This means that DMRA’s stock grew somewhat faster than VIVS’s over the last 12 months.

DMRA's P/E Growth Rating (100) in the null industry is in the same range as VIVS (100) in the Biotechnology industry. This means that DMRA’s stock grew similarly to VIVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMRAVIVS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 20 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (DMRA: $28.10 vs. VIVS: $0.28)
Brand notoriety: DMRA and VIVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMRA: 107% vs. VIVS: 7%
Market capitalization -- DMRA: $1.74B vs. VIVS: $3.76M
DMRA [@Biotechnology] is valued at $1.74B. VIVS’s [@Biotechnology] market capitalization is $3.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMRA’s FA Score shows that 1 FA rating(s) are green while VIVS’s FA Score has 1 green FA rating(s).

  • DMRA’s FA Score: 1 green, 4 red.
  • VIVS’s FA Score: 1 green, 4 red.
According to our system of comparison, DMRA is a better buy in the long-term than VIVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMRA’s TA Score shows that 4 TA indicator(s) are bullish while VIVS’s TA Score has 3 bullish TA indicator(s).

  • DMRA’s TA Score: 4 bullish, 5 bearish.
  • VIVS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both DMRA and VIVS are a bad buy in the short-term.

Price Growth

DMRA (@Biotechnology) experienced а -6.52% price change this week, while VIVS (@Biotechnology) price change was +1.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

DMRA is expected to report earnings on Oct 30, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DMRA
Daily Signal:
Gain/Loss:
VIVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REZI19.110.28
+1.49%
Resideo Technologies
LNT67.260.01
+0.01%
Alliant Energy Corp
FMFC0.20N/A
-0.95%
Kandal M Venture Limited
HY33.61-0.43
-1.26%
Hyster-Yale Inc.
EVTL0.54-0.02
-3.29%
Vertical Aerospace Ltd

DMRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMRA has been loosely correlated with COGT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DMRA jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMRA
1D Price
Change %
DMRA100%
+4.69%
COGT - DMRA
49%
Loosely correlated
-1.97%
NERV - DMRA
45%
Loosely correlated
-0.24%
INBX - DMRA
44%
Loosely correlated
-1.93%
RANI - DMRA
44%
Loosely correlated
+2.51%
GNTA - DMRA
38%
Loosely correlated
-2.38%
More

VIVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIVS has been loosely correlated with DMRA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVS jumps, then DMRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIVS
1D Price
Change %
VIVS100%
-5.57%
DMRA - VIVS
38%
Loosely correlated
+4.69%
ORMP - VIVS
37%
Loosely correlated
-2.10%
AEON - VIVS
27%
Poorly correlated
+12.72%
ACET - VIVS
27%
Poorly correlated
-0.10%
KRRO - VIVS
26%
Poorly correlated
+5.74%
More